Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.

CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges

Chen, Ming, Xu, Jiang, Zhou, Yang, Zhang, Silin, Zhu, Di · 2020 · Briefings in Functional Genomics

Abstract

Cancer immunotherapy, consisting of antibodies, adoptive T-cell transfer, vaccines and cytokines, is a novel strategy for fighting cancer by artificially stimulating the immune system. It has developed rapidly in recent years, and its efficacy in hematological malignancies and solid tumors has been remarkable. It is regarded as one of the most promising methods for cancer therapy. The current trend in immunotherapy research seeks to improve its efficacy and to ensure the safety of cancer immunotherapy through the use of gene editing technologies. As it is an efficient and simple technology, the CRISPR-Cas9 system is highly anticipated to dramatically strengthen cancer immunotherapy. Intensive research on the CRISPR-Cas9 system has provided increasing confidence to clinicians that this system can be put into clinical use in the near future. This paper reviews the application and challenges of CRISPR-Cas9 in this field, based on various strategies including adaptive cell therapy and antibody therapy, and also highlights the function of CRISPR/Cas9 in the screening of new cancer targets.

Overview

Integrity signals

Registry

Crossref · 10.1093/bfgp/elz027

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 65 references

Cited by

See all 12

Metadata

Authors
Chen, M., Xu, J., Zhou, Y., Zhang, S., & Zhu, D.
Affiliations
  • Bengbu Medical College (CN)
  • Department of Rehabilitation, Huai'an Second People's Hospital, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China, 223001
  • Fudan University (CN)
  • Renmin Hospital of Wuhan University (CN)
Corresponding author
  • Zhang, Silin
  • Zhu, Di
Venue
Briefings in Functional Genomics
Published
2019-12-02
Volume
19
Issue
3
Pages
183-190
ISSN
  • 2041-2647 (ISSN-L)
  • 2041-2657
OpenAlex
W2992262155
Cited by
12
References
65
Citations by year
2026: 1 · 2025: 4 · 2024: 3 · 2022: 1 · 2021: 1 · 2020: 2
FWCI
0.33
Type
journal article
Language
en
Open access
closed
Locations
  • Briefings in Functional Genomics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Project on Joint Translational Research of the School of Pharmacy and Minhang Hospital (RO-MY201712)
  • National Natural Science Foundation of China (81872895)
  • Projects on Science and Technology Commission of Shanghai (18ZR1403900)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
CRISPR/Cas9, genome editing, cancer immunotherapy, adoptive T cell therapy, antibody therapy, cancer vaccines, cytokines, hematologic malignancies, solid tumors, gene editing safety
MeSH terms
Gene Editing, Humans, Immunotherapy, Neoplasms, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges. https://app.cochat.ai/papers/10.1093/bfgp/elz027
The paper
Chen, M., Xu, J., Zhou, Y., Zhang, S., & Zhu, D. (2020). CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges. Briefings in Functional Genomics. https://doi.org/10.1093/bfgp/elz027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.